EP2017620A3 — Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (DPP1)
Assigned to Bayer Pharma AG · Expires 2009-04-22 · 17y expired
What this patent protects
The invention provides a human DPP1 which is associated with cancer. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cancer. The invention also features compounds which bind to and/or activate or inhibit the activity…
USPTO Abstract
The invention provides a human DPP1 which is associated with cancer. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cancer. The invention also features compounds which bind to and/or activate or inhibit the activity of DPP1 as well as pharmaceutical compositions comprising such compounds.
Drugs covered by this patent
- Brinsupri (BRENSOCATIB) · Insmed Inc
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.